BioCryst Pharmaceuticals Inc
BCX17725
Netherton syndrome
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for BCX17725 in Netherton syndrome are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“A Phase 1 trial of BCX17725, an investigational KLK5 inhibitor for the treatment of Netherton syndrome, is currently enrolling and has begun dosing patients. The company expects to report data from this program in up to 12 patients by the e”